Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Månsson, Marianne ^a   Kalies, Inge ^a   Bergström, Göran ^b   Schmidt, Caroline ^b   Legnehed, Anne ^a   Hultén, Lillemor Mattsson ^c   Amrot Fors, Lena ^a   Gustafsson, David ^a   Knecht, Wolfgang ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

AGED; ANALYSIS OF VARIANCE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; FEMALE; FIBRINOLYSIS; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; ANALYSIS OF VARIANCE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE B2; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIS; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84902770314     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05318     Document Type: Article

References (55)

1. Kronenberg, F. & Utermann, G. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273, 6-30 (2013).
2. Jenner, J. L. et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87, 1135-1141 (1993). (Pubitemid 23110386)
3. Nordestgaard, B. G. & Tybjærg-Hansen, A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr. Opin. Lipidol. 22, (2011).
4. Tsimikas, S. & Hall, J. L. Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease. J. Am. Coll. Cardiol. 60, 716-721 (2012).
5. Enkhmaa, B., Anuurad, E., Zhang, W., Tran, T. & Berglund, L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab. Syndr. Relat. Disord. 9, 411-418 (2011).
6. Erqou, S. et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA-Journal of the American Medical Association 302, 412-423 (2009).
7. Helgadottir, A. et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol. 60, 722-729 (2012).
8. Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
9. Kamstrup, P. R., Tybjærg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA-Journal of the American Medical Association 301, 2331-2339 (2009).
10. Kamstrup, P. R., Tybjærg-Hansen, A. & Nordestgaard, B. G. Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 32, 1732-1741 (2012).
11. Thanassoulis, G. et al.GeneticAssociations with Valvular Calcification andAortic Stenosis. N. Engl. J. Med. 368, 503-512 (2013).
12. Mora, S. et al. Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56, 1252-1260 (2010).
13. Boronat, M. et al. High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain. CardiovascularDiabetology 11, 81 (2012).
14. Qi, Q., Workalemahu, T., Zhang, C., Hu, F. B. & Qi, L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. European Heart Journal 33, 325-334 (2012).
15. Neele, D. M., DeWit, E. C. & Princen, H. M. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 42, 41-44 (1999). (Pubitemid 29039735)
16. Koschinsky, M. L. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc. Hematol. Disord. Drug Targets 6, 267-278 (2006). (Pubitemid 44890588)
17. Nordestgaard, B. G. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844-2853 (2010).
18. Anuurad, E., Boffa, M. B., Koschinsky, M. L. & Berglund, L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26, 751-772 (2006). (Pubitemid 44716507)
19. Feric, N. T., Boffa, M. B., Johnston, S. M. & Koschinsky, M. L. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 6, 2113-2120 (2008).
20. Angles-Cano, E., Dela Pena Diaz, A. & Loyau, S. Inhibition of fibrinolysis by lipoprotein(a). Ann. N. Y. Acad. Sci. 936, 261-275 (2001). (Pubitemid 32613913)
21. Hancock, M. A., Boffa, M. B.,Marcovina, S. M., Nesheim,M. E. & Koschinsky, M. L. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278, 23260-23269 (2003).
22. Liu, J., Harpel, P. C. & Gurewich, V. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 33, 2554-2560 (1994). (Pubitemid 24099663)
23. Alzahrani, S. H.&Ajjan, R. A. Coagulation and fibrinolysis in diabetes. Diab Vasc. Dis. Res. 7, 260-273 (2010).
24. Dunn, E. J., Philippou, H., Ariens, R. A. & Grant, P. J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49, 1071-1080 (2006).
25. Collet, J. P. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 26, 2567-2573 (2006). (Pubitemid 44607482)
26. Bochenek, M., Zalewski, J., Sadowski, J. & Undas, A. Type 2 diabetes as amodifier of fibrin clot properties in patients with coronary artery disease. J. Thromb. Thrombolysis 35, 264-270 (2013).
27. Brohall, G., Behre, C. J., Hulthe, J., Wikstrand, J. & Fagerberg, B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 29, 363-367 (2006). (Pubitemid 44106519)
28. Kamstrup, P. R. & Nordestgaard, B. G. Lipoprotein(a) is causally associated with type 2 diabetes. 81st EAS Congress (2013) (Date of access 11 April 2014) http://w3. kenes-group.com/apps/eas2013/abstracts/pdf/1177.pdf.
29. Kamstrup, P. R., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Lipoprotein(a) and risk of myocardial infarction-genetic epidemiologic evidence of causality. Scand. J. Clin. Lab. Invest. 71, 87-93 (2011).
30. Kostner, K. M.,Marz, W. & Kostner, G. M. When should we measure lipoprotein (a)? Eur. Heart J. 34, 3268-3276 (2013).
31. Kronenberg, F., Lobentanz, E. M., Konig, P., Utermann, G. &Dieplinger, H. Effect of sample storage on themeasurement of lipoprotein[a], apolipoproteins B and AIV, total and high density lipoprotein cholesterol and triglycerides. J. Lipid Res. 35, 1318-1328 (1994). (Pubitemid 2110236)
32. Simo, J. M. et al. Instability of lipoprotein(a) in plasma stored at-70 degrees C: effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. Clin. Chem. 47, 1673-1678 (2001). (Pubitemid 32781582)
33. Wieringa, G. et al. Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. Growth Horm. IGF Res. 10, 14-19 (2000). (Pubitemid 30186954)
34. Simonsson,M., Schmidt, C., Sigurdardottir, V., Helenius, M. & Fagerberg, B. Life style habits such as alcohol consumption and physical activity in relation to serum apoB/apoA-I ratio amongst 64-year-old women with varying degrees of glucose tolerance. Jornal of Internal Medicine 262, 537-544 (2007). (Pubitemid 47620510)
35. Balogh, E. et al. Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: a casecontrol study. Thromb. Res. 129, 133-138 (2012).
36. Undas, A. & Ariens, R. A. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 31, e88-99 (2011).
37. Dunn, E. J., Ariens, R. A. & Grant, P. J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48, 1198-1206 (2005). (Pubitemid 40909657)
38. Jorneskog, G., Hansson, L. O., Wallen, N. H., Yngen, M. & Blomback, M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J. Thromb. Haemost. 1, 1195-1201 (2003).
39. Alzahrani, S. H. et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J. Clin. Endocrinol. Metab. 97, E2282-7 (2012).
40. Van Giezen, J. J., Wahlund, G. Nerme & Abrahamsson, T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemost. 77, 964-969 (1997). (Pubitemid 27239123)
41. Undas, A., Stepien, E., Tracz, W. & Szczeklik, A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J. Thromb. Haemost. 4, 973-975 (2006).
42. Undas, A., Kolarz, M., Kopec, G. & Wieslawa, T. Altered fibrin clot properies in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 23, 2010 (2008).
43. Undas, A., Slowik, A.,Wolkow, P., Szczudlik, A.&Tracz, W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb. Res. 125, 357-361 (2010).
44. Pera, J. et al. Fibrin clot properties in acute stroke: what differs cerebral hemorrhage from cerebral ischemia? Stroke 43, 1412-1414 (2012).
45. Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998). (Pubitemid 28319935)
46. Prahl, U. et al. Slightly elevated high-sensitivity C-reactive protein (hsCRP) concentrations are associated with carotid atherosclerosis in women with varying degrees of glucose tolerance. Angiology 61, 793-801 (2010).
47. Ryndel, M. et al. The haptoglobin 2-2 genotype is associated with carotid atherosclerosis in 64-year old women with established diabetes. Clin. Chim. Acta 411, 500-504 (2010).
48. Fagerberg, B., Kellis, D., Bergstrom, G. & Behre, C. J. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J. Intern. Med. 269, 636-643 (2011).
49. Deming, W. E. in Statistical adjustment of data (Wiley, NY, 1943).
50. Pieters, M., Kotze, R. C., Jerling, J. C., Kruger, A. & Ariens, R. A. Evidence that fibrinogen gamma' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. Blood 121, 3254-3260 (2013).
51. Leurs, J. et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb. Haemost. 89, 264-271 (2003). (Pubitemid 36227277)
52. Meltzer, M. E. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116, 113-121 (2010).
53. Bjorquist, P., Ehnebom, J., Inghardt, T. & Deinum, J. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator. Biochim. Biophys. Acta 1341, 87-98 (1997). (Pubitemid 27357037)
54. Eriksson, H. et al. CPU inhibtion with AZD9684: profibrinolytic effects in acute patients. J Thromb Haemost 5, PS 367 (2007). 55.
55. Undas, A. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114, 4272-4278 (2009).